Dopamine Agonist Withdrawal Syndrome (DAWS)

Physician Article Dr. Brian Harris
Dopamine Agonist Withdrawal Syndrome (DAWS)
Why this matters

Some withdrawals are underestimated mainly because they are inconvenient to believe in. Dopamine Agonist Withdrawal Syndrome (DAWS) belongs on that list. When stopping medications like pramipexole or ropinirole creates its own severe psychological and physical "crash," the answer is careful planning, not disbelief.

In plain language

If you’ve been taking dopamine-boosting drugs for RLS and decide to stop, you might experience more than just the return of your leg symptoms. DAWS is a real withdrawal syndrome that can feel like a sudden, deep "crash."

Symptoms can include:

  • Intense anxiety or panic.
  • Depressed mood and loss of interest in things.
  • Sweating, nausea, or dizziness.
  • Severe insomnia.

Because these symptoms are so difficult, people often rush back to the medication just to feel "normal" again. To get off these drugs successfully, you need a slow, medically supervised taper and a backup plan for managing your RLS during the transition.

Clinical deep dive

Dopamine Agonist Withdrawal Syndrome (DAWS) is a clinically significant condition that occurs during the tapering or discontinuation of dopaminergic medications.

Pathophysiology

DAWS is thought to result from the sudden withdrawal of dopaminergic stimulation in the mesolimbic reward system. This is separate from the "motor" withdrawal of RLS symptoms. It mirrors the withdrawal seen in other substance use disorders, reflecting a state of hypodopaminergia.

Clinical Presentation

  • Neuropsychiatric: Severe anxiety, agitation, depression, and suicidal ideation.
  • Autonomic: Orthostatic hypotension, diaphoresis, and nausea.
  • Physical: Pain and profound insomnia.

Management Strategy

There is no "gold standard" for managing DAWS, making prevention (avoiding high-dose dopamine agonists) the best strategy. For patients already in withdrawal: 1. Re-titration: Sometimes the dose must be increased slightly to stabilize the patient before attempting a much slower taper. 2. Replacement: Initiating alpha-2-delta ligands or iron repletion to manage the underlying RLS motor symptoms. 3. Psychological Support: Counseling patients that the neuropsychiatric symptoms are a physiological part of withdrawal, not necessarily a new "mental health" diagnosis.